DOI:
10.1055/s-00000142
Frauenheilkunde up2date
LinksClose Window
References
Gelmon KA, Tischkowitz M, Mackay H. et al.
Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study.
Lancet Oncology 2011;
12: 852-861
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.